Evolving kidney disease phenotypes in type 2 diabetes: declining albuminuria and increasing isolated low eGFR
De Cosmo S, Russo G, Nicolucci A, et al.
Clin Kidney J. Pub. online 2 Mar 2026.
Leggi
Impact of continuous glucose monitor on health care resource utilization in adults with type 2 diabetes managed by noninsulin therapies
Sharma AK, Lee A, Mehta S, et al.
Diabetes Technol Ther. Pub. online 1 Mar 2026.
Leggi
Insulin delivery modality and Ramadan fasting interruption, glycemic control, and fear of hypoglycemia in type 1 diabetes: a prospective, multicenter study from Saudi Arabia
Al-Sofiani ME, Alharthi SK, Alsuhaibani M, et al.
Diabetes Res Clin Pract. Pub. online 2 Mar 2026.
Leggi
Gestational diabetes, glycemic management trajectories, and offspring growth patterns and obesity risk
Chehab RF, Greenberg MB, Lee C, et al.
Diabetes Care. Pub. online 4 Mar 2026.
Leggi
Comparative effectiveness of tirzepatide versus dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes and cardiovascular disease: insights from two target-trial emulations
Ostrominski JW, Ortega-Montiel J, Wexler DJ, et al.
Diabetes Care. Pub. online 2 Mar 2026.
Leggi
Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial
Nordanstig J, Arslan EG, Catarig AM, et al.
Eur Heart J. Pub. online 5 Mar 2026.
Leggi
Everyone or just some? cost-effectiveness of general population versus targeted screening strategies for type 1 diabetes in Canada
Mital S, Schatz DA, Haller MJ, et al.
Diabetes Care. Pub. online 2 Mar 2026.
Leggi
Small extracellular vesicle external surface adiponectin-mediated adipocytes/cardiomyocytes communication in diabetic ischemic heart failure
Zhang Z, Zhu D, Liu C, et al.
Circulation. Pub. online 2 Mar 2026.
Leggi
NUOVO PERCORSO SCIENTIFIC TALK E OCCHIO AL TRIAL AMD 2026
Carissimi Soci, primo percorso 2026 in combinazione Scientific Talk e Occhio al Trial AMD: “Colmare il gap tra evidenza, linee guida ed innovazione digitale nella cura del DMT2”. L’iniziativa, accreditata ECM, prevede tre appuntamenti: 25 Marzo 1° Scientific Talk “Prevenzione del rischio: Empaglifozin come strategia precoce per la protezione cardiovascolare e renale” M. Manunta…
Leggi
Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach
Alexander L, Purnell JQ, Burridge K, et al.
Obesity (Silver Spring). Pub. online 5 Mar 2026.
Leggi